Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
长寿初创公司完成首例人体给药，旨在逆转与年龄相关的视力丧失
A longevity startup has dosed its first patient with a drug to reverse age-related sight loss. 一家长寿初创公司已为其首位患者注射了一种旨在逆转与年龄相关视力丧失的药物。
Life Biosciences is testing its ER-100 drug, which the company claims has restored vision in monkeys, for safety and side effects in a study of around 18 adults over the next year. Life Biosciences 正在对其 ER-100 药物进行测试。该公司声称该药物已在猴子身上成功恢复了视力，目前正通过一项为期一年的研究，对约 18 名成年人进行安全性及副作用评估。
It will be targeting patients with glaucoma and NAION, two conditions that cause damage to crucial cells in the optic nerve, which transmits visual information from the back of the eye to the brain. ER-100 is designed to rejuvenate those cells so that they work again and restore sight. 该研究将针对青光眼和非动脉炎性前部缺血性视神经病变（NAION）患者。这两种疾病都会损害视神经中的关键细胞，而视神经负责将视觉信息从眼后部传输到大脑。ER-100 的设计初衷是使这些细胞恢复活力，从而使其重新发挥作用并恢复视力。
It is the first-ever cellular-rejuvenation therapy using this technology to receive FDA clearance to enter human clinical trials, and hence the first chance to test whether the technology can “ameliorate human disease,” according to Life Biosciences cofounder David Sinclair, who is also a professor of genetics at Harvard Medical School. 这是首个获准进入人体临床试验的此类细胞再生疗法。Life Biosciences 联合创始人、哈佛医学院遗传学教授大卫·辛克莱（David Sinclair）表示，这是首次有机会验证该技术是否能够“改善人类疾病”。
Aging biology—understanding how the body’s cells and functions deteriorate over time—is at the root of longevity science. ER-100 is the focus of major interest across biotech for its potential to reverse cellular aging. Life Biosciences, based in Boston, says it is developing applications for its technology to tackle a host of age-related diseases in a variety of organs, like fatty liver disease. 衰老生物学——即理解人体细胞和功能如何随时间推移而退化——是长寿科学的根基。ER-100 因其逆转细胞衰老的潜力，正受到生物技术领域的广泛关注。总部位于波士顿的 Life Biosciences 表示，该公司正在开发相关技术应用，以解决多种器官中与年龄相关的疾病，例如脂肪肝。
“Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease,” Sinclair said. 辛克莱表示：“我们的研究表明，衰老在很大程度上是由表观遗传信息的丢失驱动的，而非不可逆的损伤。这项临床研究代表了我们首次有机会测试恢复这些信息是否能够改善人类疾病。”